Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas.
Jing WuYing YuanDebra A Long PrielDanielle FinkCody J PeerTristan M SissungYu-Ting SuYing PangGuangyang YuMadison K ButlerTito R MendozaElizabeth VeraSalman AhmadChristine BrylaMatthew LindsleyEwa GrajkowskaKelly MentgesLisa BorisRamya AntonyNancy GarrenChristine SiegelNicole LolloChristine CordovaOrwa AboudBrett J TheelerEric M BurtonMarta Penas-PradoHeather E LeeperJavier GonzalesTerri S ArmstrongKatherine R CalvoWilliam Douglas FiggDouglas B KuhnsJohn I GallinMark R GilbertPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Zotiraciclib combined with temozolomide is safe in patients with recurrent high-grade astrocytomas. Zotiraciclib-induced neutropenia can be profound but mostly transient, warranting close monitoring rather than treatment discontinuation. Once validated, polymorphisms predicting drug metabolism may allow personalized dosing of zotiraciclib.